INmune Bio, Inc. (NASDAQ: INMB) reported Q3 EPS of ($0.48), $0.08 worse than the analyst estimate of ($0.40). Revenue for the quarter came in at $43 thousand versus the consensus estimate of $46 thousand.

For earnings history and earnings-related data on INmune Bio, Inc. (INMB) click here.